Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Small wins
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
S2CID 23738007
These findings are being licensed by Circular Genomics, which is developing clinical assays (lab tests) that could reshape the standard of care for the early identification of neurological and psychiatric diseases like Alzheimers
US$ 29.64
US$ 25.18
US$ 20.02
US$ 26.14
